Navigation Links
Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
Date:11/7/2011

LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 /PRNewswire/ -- Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries (collectively, "Planet"), a privately held specialty pharmaceutical company focused on providing products for allergy and asthma sufferers, today announced that it had completed an asset sale of ALLERGY CONTROL PRODUCTS, INC., a Delaware corporation("ACP") to RH ALLERGY ACQUISITION LLC, a New Jersey limited liability company.

Theron E. Odlaug, Ph. D., CEO and Executive Chairman of Planet, commented, "The sale of this business is in line with our strategy to focus on our allergenic extract business through our wholly owned subsidiaries Antigen Laboratories, Inc. and ALO, Inc.  We plan to merge these two remaining Planet subsidiaries at year-end".

Jeffrey Tauber, Managing Member of RH Allergy Acquisition noted "We are excited about this acquisition as it is a logical extension of our allergy prevention and environmental control business. We look forward to a smooth transition and will continue to maintain ACP's offices in Danbury, Connecticut."

For more information about Antigen Laboratories, Inc, please visit http://www.antigenlab.com/


'/>"/>
SOURCE Planet Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment
2. WellSpring Pharmaceutical, American Gastroenterological Association, and Steven Bramson of Humanscale Partner With MediaPlanet to Publish One of the Largest Digestive Wellness Campaigns in U.S. History to Overcome Upset Stomach, Nausea, IBS, and Deb
3. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
4. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
Breaking Medicine News(10 mins):